September 8, 2021

Braxia Scientific (BRAX) Developing Ketamine Treatments of the Future

Midas Letter
Midas Letter
Braxia Scientific (BRAX) Developing Ketamine Treatments of the Future
/

Braxia Scientific Corp (CNSX:BRAX, OTCMKTS:BRAXF) is a medical research psychedelics company that owns a global network of clinics providing innovative ketamine treatments for persons with depression and related disorders. The company successfully expanded its network of multidisciplinary clinics to four earlier this year, with one of the very few private intravenous ketamine treatment clinics approved in Canada.

Braxia Scientific is also developing psychedelic drug formulations related to Ketamine and Esketamine. The company’s clinics are advancing multiple research and development studies and conducting clinical trials with psychedelic derivatives and IP-capable delivery methods.

The Company recorded revenues of $1,008,372  and gross margins of was approximately 17.3% as a percentage of total revenue in the last year. Revenues consisted primarily of sales revenue from the administering of ketamine infusion treatments at the company’s clinics.

Braxia expects to add to its clinic footprint in 2021 and continue carrying out several clinical trials. The attractive point for investors is the fact Braxia’s clinical trials will mostly be funded by third parties.

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.